Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease

被引:8
作者
Rigor, Joana [1 ,2 ,9 ]
Vasconcelos, Raquel [3 ]
Lopes, Rogerio [3 ]
Moreira, Teresa [3 ]
Barata, Pedro [4 ,5 ,6 ]
Martins-Mendes, Daniela [2 ,6 ,7 ,8 ]
机构
[1] Vila Nova de Gaia Espinho Hosp Ctr, Dept Internal Med, Vila Nova De Gaia, Portugal
[2] Univ Porto, Dept Biomed, Fac Med, Porto, Portugal
[3] Vila Nova de Gaia Espinho Hosp Ctr, Dept Radiol, Vila Nova De Gaia, Portugal
[4] Fernando Pessoa Univ, Fac Hlth Sci, Porto, Portugal
[5] Porto Univ Hosp, Dept Pathol, Porto, Portugal
[6] Univ Porto, I3S Inst Hlth Res & Innovat, Porto, Portugal
[7] Fernando Pessoa Univ Hosp, Dept Internal Med, Porto, Portugal
[8] Polytech Inst Porto, PORTIC Porto Res Technol & Innovat Ctr, LaBMI Biotech Solut, Porto, Portugal
[9] Vila Nova de Gaia Espinho Hosp Ctr, Serv Internal Med, Rua Conceicao Fernandes S-N, P-4434502 Vila Nova De Gaia, Portugal
来源
MINERVA GASTROENTEROLOGY | 2023年 / 69卷 / 03期
关键词
Non-alcoholic fatty liver disease; Fibrosis; Sarcopenia; Muscle strength; Body composition; BODY-COMPOSITION; SARCOPENIA; FIBROSIS; NAFLD; STEATOHEPATITIS; OBESITY; SCORE;
D O I
10.23736/S2724-5985.22.03097-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a rising global health issue. The influence of muscle in its pathophysiology has recently gained attention. Our aim was to investigate the association of low muscle mass, strength, and performance with the presence and severity of NAFLD.METHODS: Patients with metabolic syndrome followed in an outpatient clinic, were consecutively included, between April 1st and December 31st, 2019. Abdominal ultrasound for the diagnosis of NAFLD, NAFLD fibrosis score (NFS) and Fibrosis-4 Index (FIB-4) for determination of significant fibrosis, dual-energy X-ray absorptiometry for calculation of skeletal muscle index (SMI = appendicular skeletal mass / weight x100) and sarcopenic index (SI = appendicular skeletal mass / Body Mass Index), and the Short Physical Performance Battery for muscle strength and performance assessment were performed. Sarcopenia was defined as low muscle strength and low SMI or SI.RESULTS: A total of 157 patients were included, of which 68.8% had NAFLD, 66.2% low SMI, 50.3% low SI, 16.6% low performance and 11.5% low strength. In patients with NAFLD, prevalence of significant fibrosis by NFS was 15.7%. Low SMI was associated with presence of NAFLD when adjusted for age, sex, type 2 diabetes mellitus, hypertension, and dyslipidemia, but not for body mass index and waist circumference. Low SMI, low SI, and sarcopenia were associated with significant fibrosis in univariate analysis; the small number of events precluded a multivariable analysis.CONCLUSIONS: Low SMI was associated with NAFLD independently of demographics and comorbidities but not of other parameters of body composition. This contrasts with most studies published on this matter.(Cite this article as: Rigor J, Vasconcelos R, Lopes R, Moreira T, Barata P, Martins-Mendes D. Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease. Minerva Gastroenterol 2023;69:374-81. DOI: 10.23736/S2724-5985.22.03097-2)
引用
收藏
页码:374 / 381
页数:8
相关论文
共 46 条
[31]   Association of grip strength with non-alcoholic fatty liver disease: investigation of the roles of insulin resistance and inflammation as mediators [J].
Park, Seung Ha ;
Kim, Dong Joon ;
Plank, Lindsay D. .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2020, 74 (10) :1401-1409
[32]   Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition [J].
Peng, Tao-Chun ;
Wu, Li-Wei ;
Chen, Wei-Liang ;
Liaw, Fang-Yih ;
Chang, Yaw-Wen ;
Kao, Tung-Wei .
CLINICAL NUTRITION, 2019, 38 (01) :422-428
[33]   Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease [J].
Petta, S. ;
Ciminnisi, S. ;
Di Marco, V. ;
Cabibi, D. ;
Camma, C. ;
Licata, A. ;
Marchesini, G. ;
Craxi, A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (04) :510-518
[34]   Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014 [J].
Saracco, Giorgio Maria ;
Evangelista, Andrea ;
Fagoonee, Sharmila ;
Ciccone, Giovannino ;
Bugianesi, Elisabetta ;
Caviglia, Gian Paolo ;
Abate, Maria Lorena ;
Rizzetto, Mario ;
Pellicano, Rinaldo ;
Smedile, Antonina .
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (36) :8187-8193
[35]  
Sciarrone SS, 2021, MINERVA GASTROENTERO, V67, P11, DOI 10.23736/S2724-5985.20.02776-2
[36]   Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes [J].
Seo, D. H. ;
Lee, Y-H ;
Park, S. W. ;
Choi, Y. J. ;
Huh, B. W. ;
Lee, E. ;
Huh, K. B. ;
Kim, S. H. ;
Cha, B-S .
DIABETES & METABOLISM, 2020, 46 (05) :362-369
[37]   Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease [J].
Shah, Amy G. ;
Lydecker, Alison ;
Murray, Karen ;
Tetri, Brent N. ;
Contos, Melissa J. ;
Sanyal, Arun J. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (10) :1104-1112
[38]   Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection [J].
Sterling, Richard K. ;
Lissen, Eduardo ;
Clumeck, Nathan ;
Sola, Ricard ;
Correa, Mendes Cassia ;
Montaner, Julio ;
Sulkowski, Mark S. ;
Torriani, Francesca J. ;
Dieterich, Doug T. ;
Thomas, David L. ;
Messinger, Diethelm ;
Nelson, Mark .
HEPATOLOGY, 2006, 43 (06) :1317-1325
[39]   The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates [J].
Studenski, Stephanie A. ;
Peters, Katherine W. ;
Alley, Dawn E. ;
Cawthon, Peggy M. ;
McLean, Robert R. ;
Harris, Tamara B. ;
Ferrucci, Luigi ;
Guralnik, Jack M. ;
Fragala, Maren S. ;
Kenny, Anne M. ;
Kiel, Douglas P. ;
Kritchevsky, Stephen B. ;
Shardell, Michelle D. ;
Dam, Thuy-Tien L. ;
Vassileva, Maria T. .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2014, 69 (05) :547-558
[40]  
Tovo CV, 2017, WORLD J HEPATOL, V9, P326, DOI 10.4254/wjh.v9.i6.326